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Summary Oestrone sulphatase is an important source of local synthesis of biologically active oestrogens in
human breast cancer. The oestrone sulphatase enzyme in the particulate fraction of human breast carcinoma
was characterised. The Km was 8.91 gM, and the V. was 0.022 nmol min- mg-. Oestrone sulphatase activity
was detected in 93 of 104 human breast carcinoma samples (89%), and mean activity was
0.041 nmol min-' mg -' (range 0-0.399 nmol min-' mg-'). There was no significant correlation between
intratumoral oestrone sulphatase activity and oestrogen receptor status, or with any other prognostic factors.
Intratumoral enzyme levels were not associated with time to recurrence or with overall survival time. It thus
appears that, although a useful source of intratumoral oestrogens, oestrone sulphatase activity is not of
prognostic significance in breast carcinoma.
Approximately one-third of human breast carcinomas are
hormone dependent (Henderson & Canellos, 1980). Animal
studies and clinical trials of anti-oestrogens and inhibitors of
oestrogen biosynthesis have confirmed that oestrogens are the
most important hormones involved in supporting growth of
hormone-dependent breast cancers (Segaloff, 1978; Kir-
schner, 1979). Indeed, oestrogen deprivation by these means
results in objective tumour regression.
Plasma levels of oestrone and oestradiol in post-
menopausal women are very low, however the oestrogen
concentration in breast carcinoma tissues is an order of
magnitude higher than in the plasma (Millington, 1975),
suggesting local intratumoral production of oestrogens in
breast cancer cells from precursor substrates. It was
originally considered that the predominant source of oest-
rogen production in post-menopausal women is the extra-
glandular conversion of androstenedione to oestrone by
peripheral tissues catalysed by the aromatase enzyme (Grodin
et al., 1973). However oestrone sulphate is the most abun-
dant oestrogen in peripheral blood (Loriaux et al., 1971), and
plasma oestrone sulphate levels are higher in post-meno-
pausal women with breast cancer than in normal post-
menopausal women (Prost et al., 1984). Studies involving
MCF-7 cell lines have shown that oestrone sulphate itself is
unable to bind to the oestrogen receptor (OR) and stimulate
a biological response, but can be taken up by these cells and
hydrolysed to unconjugated oestrone in amounts sufficient to
stimulate a biological response (Pasqualini et al., 1989).
Hydrolysis of oestrone sulphate to oestrone by human
breast carcinoma tissue has been demonstrated by several
groups (Wilking et al., 1980; Carlstrom et al., 1984; Prost et
al., 1984; Santner et al., 1984; Naitoh et al., 1989). Wilking et
al. (1980) found oestrone sulphatase activity in all of 23
human breast carcinoma samples assayed; Prost et al. (1984)
found oestrone sulphatase activity in all of 21 tumours
assayed, and Santner et al. (1984) found oestrone sulphatase
activity in all of 35 tumours assayed. There was no correla-
tion between oestrone sulphatase activity and OR status in
all three studies. In contrast, higher levels of oestrone sul-
photransferase, which catalyses the formation of oestrone
sulphate from oestrone, have been found in breast cancer
samples which are positive for both oestrogen and pro-
gesterone receptors (Adams et al., 1979; Pewnim et al., 1980).
Intratumoral oestrone sulphatase activity is higher than in
surrounding normal breast tissue (Naitoh et al., 1989).
Correspondence: T.R.J. Evans.
Received 6 May 1993; and in revised form 24 August 1993.
Moreover, a comparative study of oestrone sulphatase and
aromatase activities in human breast cancer samples sug-
gested that the oestrone sulphatase pathway is the
predominant source of intratumoral oestrogen production in
post-menopausal women (Santner et al., 1984). Moreover,
the biological effects demonstrated in response to physio-
logical concentrations of oestrone sulphate in MCF-7 cell
cultures provide further evidence of the relevance of this
pathway in the production of intratumoral oestrogens in
breast carcinoma tissues (Santner et al., 1993).
Previous work from our laboratory has demonstrated a
significant correlation between intratumoral aromatase
activity and histological grade in human breast carcinoma,
but no correlation either with other prognostic factors or
with overall survival (Silva et al., 1989). Consequently, we
considered it pertinent to investigate further intratumoral
oestrone sulphatase activity as a prognostic factor in human
breast cancer, and its relationship to other factors believed to
be of prognostic value.
Materials and methods
Reagents
[6,7-3H]oestrone sulphate (specific activity 47.7 Cimmol')
was purchased from New England Nuclear Division (Du
Pont, UK). Purity was checked by thin-layer chromato-
graphy (TLC) (Silica gel Merck 5415 Kieselgel F254) using
the following solvent system: ethyl acetate-methanol-
ammonium hydroxide (75:25:2, v/v). [14-'4C]oestrone
(specific activity 60Cimmol[') was purchased from Amer-
sham International (Amersham, UK). Unlabelled oestrone
sulphate was purchased from Sigma (Poole, UK).
Tissues and tissuepreparation
Human breast carcinoma samples were obtained from the
tissue bank of the Oncology Department, St. George's Hos-
pital Medical School, London, UK. All samples had been
stored in liquid nitrogen for between 1 and 10 years.
All procedures were carried out at 0-4°C. Human breast
carcinoma tissues were chopped with scissors and dissolved
in 0.25 M sucrose in 50 mM Tris-HCl buffer, pH 7.4 (1 g of
tissue to 10 ml of buffer), then homogenised with a Polytron
for a period of 15 s. The homogenate was subjected to
subcellular fractionation. The nuclear pellet was obtained by
centrifugation at 1,500g for 15 min, followed by centrifuga-
tion at 100,000g for 70 min to separate the particulate frac-
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tion from the cytosol. All pellets were resuspended in
50 mM Tris-HCI buffer, pH 7.4, and together with the
cytosols were snap frozen at -80°C and stored at -20°C.
All samples were assayed for oestrone sulphatase activity and
the protein content determined by the method of Hartree
(1972).
Oestrone sulphatase assay
Before use in the assay, oestrone sulphate was purified by
solvent partition with diethyl ether (5:1, v/v) in order to
remove any unconjugated steroids. Radiolabelled oestrone
sulphate was added to the unlabelled compound to achieve
the required concentration. All assays were carried out in
duplicate at 37°C in a shaking water bath. Tubes were prein-
cubated for 1 min before initiating the reaction by addition
of the tissue samples. The assay tubes (vol. 0.3 ml) contained
10 mM dithiothreitol (DTT), 1 mM EDTA, 20gM [3H]oes-
trone sulphate (approximately 4 x I05 c.p.m.), tissue sample
and 50 mM Tris-HCl buffer at the optimal pH for the breast
carcinoma tissue enzyme. Control tubes contained boiled
tissue samples.
Aliquots (0.1 ml) were removed from each assay tube after
10 and 20 min incubation to ensure linearity of product
formation. The reaction was terminated by addition of each
aliquot to a chilled tube containing 0.1 M sodium carbonate
and [14-'4C]oestrone (approximately 5,000c.p.m.) as internal
standard. The unconjugated product was separated from the
substrate by adding 3 ml of ether and left to stand at room
temperature. After drying with anhydrous sodium sulphate,
the ether layer was separated by centrifugation and added to
a scintillation vial. The sample was evaporated to dryness
under nitrogen and reconstituted with 10ml of scintillation
fluid and radioactivity determined by liquid scintillation
counting. The recovery of the internal standard was used to
correct the amount of tritiated product formed.
The method was modified in order to identify the products
of the oestrone sulphatase enzyme. The extracted ether phase
was dried and centrifuged as before, an aliquot of 200 tl
taken for counting and then the remainder taken to dryness
by rotary evaporation and reconstituted with a small volume
(25pl) of ethyl acetate. This sample was run on a TLC plate
using dichloromethane-ether (9:1, v/v) as solvent system.
The plates were scanned using a Berthold LB 283 linear
analyser and the radioactive peaks were scraped off the TLC
plate, the silica dissolved in methanol, an aliquot retained for
counting and the remainder taken to dryness under nitrogen
and reconstituted in 25jil of ethyl acetate as before. These
samples were run on a TLC plate using a second solvent
system, namely ethyl acetate-benzene (1:1, v/v), the plate
was scanned using the Berthold LB 283 linear analyser, and
the radioactive peaks identified and scraped off and dissolved
in methanol before counting.
The percentage conversion of tritiated substrate to product
was determined from the linear plots of product released
against time, and the mean of four determinations (duplicate
samples at two time points each) calculated. From this value
the specific oestrone sulphatase activity for each sample was
calculated. No activity was observed for the control samples.
Oestrogen receptor content
For many samples, the oestrogen receptor status was known
from the tissue bank records. For those samples in which the
OR status was not known, this was determined by an
immunocytochemical method previously described (McClel-
land et al., 1987) using an oestrogen receptor
immunocytochemistry (ERICA) kit (Abbot Laboratories).
Briefly, a frozen section of tissue was soaked in 3.7%
formaldehyde/phosphate-buffered saline (PBS) for 10 min,
and following rinsing in a PBS bath was placed sequentially
in cold methanol (3-5 min at -20°C), cold acetone
(1-3 min at -20C) then twice in PBS at room temperature
for 5 min each time. To this section was added a blocking
reagent (normal goat serum) for 15 min, followed by the
primary antibody for 30min (control antibody to control
sections), bridging antibody for 30 min then the PAP
(peroxidase-anti-peroxidase) complex for 30 min. Two rinses
of 5 min each in PBS were performed between each of these
steps. Fresh chromagen was added to the sections for 6 min,
then the sections were rinsed in distilled water, counter-
stained lightly in haematoxylin, then dehydrated and
mounted. All ERICA-stained sections were analysed by one
worker, and reported as either positive or negative, but not
quantified.
Statistical analyses
One hundred and four breast carcinoma samples were
assayed from patients who had undergone excisional biopsy
or mastectomy between 1980 and 1989 at St. George's Hos-
pital or at the Royal Marsden Hospital, London, UK.
Medical records of these patients were reviewed retrospec-
tively, and the following information recorded where possi-
ble: date of birth, age at menarche, parity and age at first
pregnancy, age at menopause, family history of breast cancer
(defined as a first-degree relative), age, weight and meno-
pausal status at diagnosis, OR status, tumour size, time to
first relapse and overall survival time.
Patients were divided into three groups of low, medium
and high oestrone sulphatase activity, the cut-off points
chosen to give roughly equally sized groups. These three
groups were then compared in terms of the variables
recorded.
All P-values quoted were calculated from tests for trend.
Continuous variables (age at diagnosis, weight at diagnosis,
age at menarche, age at first pregnancy and age at meno-
pause) were analysed using linear contrasts from a simple
analysis of variance. Non-parametric Kruskal-Wallis tests
were performed to check the robustness of the analysis of
variance to assumptions of normality. These tests gave very
similar results to the parametric tests and are not presented.
Categorical variables (all others) were analysed using chi-
square tests for trend. Time to recurrence and overall sur-
vival were analysed using the log-rank test, survival plots
being drawn using the method of Kaplan and Meier.
Results
Evaluation ofoptimal assay conditions
Under the standard assay conditions, the control tubes con-
taining boiled tissue gave no conversion of oestrone sulphate
to oestrone. The intra-assay coefficient of variation was
7.08% (n = 6), the inter-assay coefficient of variation was
7.66% (n = 8). The characterisation of breast tumour oest-
rone sulphatase activity was carried out using tissue pooled
from six patients to give a total of 5 g. Each result is from
quadruplicate determinations (n = 4) and expressed as
mean ± s.e. (assuming an experimental error of 15%).
Table I shows the specific activities of the sulphatase
enzyme in the subcellular fractions of human breast car-
cinoma tissue, and the percentage that each of these fractions
represents of the total activity seen in this tissue. The pooled
mitochondrial/microsomal fraction (the particulate fraction)
is the predominant source of enzyme activity. There was a
linear relationship of increasing enzyme activity with increas-
ing protein concentration demonstrated up to 121.5;g of
particulate fraction of breast carcinoma tissue. In addition,
there was linear product formation up to 20 min, demon-
strating that the enzyme was assayed under saturating condi-
tions.
The Km and V.. were calculated by the Lineweaver-Burk
method. In the human breast carcinoma particulate fraction,
the Km was 8.91 ± 1.3ltM, and Vm. 0.02 ± 0.005 nmol
min-' mg-' (n = 4). The reciprocal plot for this enzyme was
linear in nature with no evidence of substrate activation or
product inhibition. The optimum pH was determined over a
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sulphonic acid (MES)-sodium hydroxide, Tris-HCl and
glycine-sodium hydroxide as buffering systems. The optimum
pH and buffer for the breast particulate fraction was found
to be Tris-HCl, pH 7.2.
With both solvent systems only one radioactive peak was
seen for the breast carcinoma enzyme product, in each case
corresponding to the Rf value of cold oestrone as visualised
by UV light, where Rf is the comparative distance of the
solute and the solvent from the origin. With the dichloro-
methane-ether (9:1, v/v) system, the Rf value was 0.39. With
the ethyl acetate-benzene (1:1, v/v) system the Rf value was
0.47. The 3H/'4C ratio of the products formed remained
constant after the ether extraction and after the sequential
TLC analysis. This demonstrates that the only 3H-labelled
non-polar metabolite formed is oestrone and that this is
essentially pure at the ether extraction stage (Table II).
Intratumoral oestrone sulphatase content
Of these biopsy samples, ten patients had received local
(non-endocrine) therapy between 14 and 264 months (mean
110.3 months; median 85 months) previously for a preceding
primary tumour in the contralateral breast. At the time of
biopsy of the second primary (from which enzyme activity
was assayed), one patient had received 3 months of neo-
adjuvant endocrine therapy, and another patient was receiv-
ing endocrine therapy for metastatic disease. Fourteen sam-
ples were biopsies of local recurrence from primary tumours
Table I Specific activity of oestrone sulphatase in subcellular
fractions
Specific activity Total
Tissue fraction (nmolmin'mg-') activity (%)
Human breast carcinoma
Nuclear 0.19 0.04 18.1
Mitochrondrial/microsomal 0.89 ± 0.13 81.9
Cytosolic No activity
Homogenate 0.13 ± 0.02
Table II Purity of [3H]oestrone product of human breast carcinoma
oestrone sulphatase
Sample 3H/14C ratio
Ether extraction 5.64:1
Dichloromethane-ether (9:1) 5.52:1
Ethyl acetate-benzene (1:1) 5.53:1
0
.0
E
z
Figure 1 The distribution of intratumoral oestrone sulphatase in
104 human breast carcinoma samples.
which had been treated with local (non-endocrine) therapy
between 7 and 114 months (mean 23.5 months; median 37.6
months) previously, and two patients had received neoad-
juvant therapy (one endocrine) prior to biopsy. Four of the
patients with primary breast cancer had received neoadjuvant
endocrine therapy (up to 6 months) prior to biopsy. Three
biopsy specimens were from patients with metastatic disease,
and who had received 3-4 endocrine treatments at the time
of biopsy.
Each result is the mean of quadruplicate determinations.
As the tumour samples were small (<1 g), and as repeated
freezing and thawing would lead to degradation of enzyme
activity, it was not possible to determine if prolonged storage
in liquid nitrogen for different periods of time would result in
different enzyme activity from fresh tissue.
Intratumoral oestrone sulphatase activity was detected in
93 of 104 breast carcinoma samples assayed (89%; range
0-0.399 nmol min'l mg'l). The distribution of oestrone sul-
phatase activity in these samples is demonstrated in Figure 1.
Two patients were omitted from subsequent analyses because
of insufficient clinical data. Patients were divided into
roughly equal groups, low (<0.019 nmol min' mg-';
n ± 32), medium (0.02-0.39 nmol min-' mg-'; n = 36) or
high oestrone sulphatase activity (>0.04 nmol min lmg-';
n = 34).
Relationship ofintratumoral oestrone sulphatase to other
prognosticfactors (Table III)
Oestrogen receptor status Oestrogen receptor status was
known in 96 of 102 cases; 44 patients were OR positive and
52 were OR negative. In the low oestrone sulphatase activity
group, 15 were OR positive and 13 OR negative. In the
medium activity group 16 were OR positive and 19 were OR
negative. In the high-activity group 13 were OR positive and
20 were OR negative. There was no significant correlation
between enzyme activity and receptor status (P = 0.33).
Node status In 87 of 102 cases the presence or absence of
histologically involved regional lymph nodes was known. In
38 patients at least one lymph node was involved with
tumour, but there was no lymph node involvement in 49
cases. In the low-activity group, 14 were node positive, 13
were node negative; in the medium-activity group 13 were
node positive and 21 were node negative; in the high-activity
group 11 were node positive and 15 were node negative.
There was no significant correlation between node status and
enzyme activity (P = 0.57).
Age at the time ofdiagnosis The age at the time ofdiagnosis
was known in 97 of 102 cases. The mean age at diagnosis
was 56 ± 12 (s.d.); the median age at diagnosis was 55 (range
29-86). In the low-activity group, the mean age was 56 ± 13,
and the median age was 55 (range 36-86) for 30 patients. In
the medium-activity group the mean age was 57 ± 13 years
and the median age was 58.5 years (range 34-80) for 36
patients. In the high-activity group, the mean age was
54 ± 11 years and the median age was 52 years (range
29-74) for 31 patients. There was no significant correlation
between oestrone sulphatase activity and the age of the
patient at the time of diagnosis (P= 0.44).
Histology Histology reports were obtained from patient
records of 94 patients. There were seven cases of infiltrative
lobular carcinoma, five of ductal carcinoma in situ (DCIS)
and 79 of infiltrative ductal carcinoma (IDC). There was one
case each of anaplastic carcinoma, papillary carcinoma and
mucinous carcinoma, and for the purposes of this study these
were analysed with the IDC group. In the low-activity group,
there were 27 cases of IDC, two lobular carcinomas and one
DCIS. In the medium-activity group, there were 31 cases of
IDC, three cases of lobular carcinoma and two of DCIS. In
the high-activity group, there were 24 cases of IDC, two of
lobular carcinoma and two of DCIS. The histology was
unknown in two cases in the low-activity group, and in six
C C') LC)O cDo o' 00 0) 0
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Table III Oestrone sulphatase activity in breast cancer
Low Medium High Overall
Variable (n = 32) (n = 36) (n = 34) P-value (n = 102)
Node status
+ve
-ve
Not known
OR status
+ve
-ve
Not known
Histology
IDC
Lobular
DCIS
Not known
Age at diagnosis
Mean (s.d.)
Median (range)
Not known
Weight at diagnosis (kg)
Mean (s.d.)
Median (range)
Not known
Age at menarche
Mean (s.d.)
Median (range)
Not known
Parity
Yes
No
Not known
Age at first pregnancy
Mean (s.d.)
Median (range)
Not known
Menopausal status
Pre/peri
Post
Not known
Age at menopause
Mean (s.d.)
Median (range)
Not known
Family history
Yes
No
Not known
Tumour size
T1/T2
T3/T4
Not known
14
13
5
15
13
4
27
2
1
2
13
21
2
16
19
1
31
3
2
0
56 (13)
55 (36-86)
2
62 (13)
61 (41-89)
16
11.9 (2.1)
12 (7-15)
15
22
6
4
27 (6)
27 (17-39)
8
13
17
2
49 (7)
50 (35-56)
2
5
21
6
10
7
15
11
15
8
13
20
1
24
2
2
6
57 (13)
58.5 (34-80)
0
64 (12)
61 (39-93)
15
13.3 (1.3)
14 (9-16)
1
27
9
0
27 (6)
26 (19-39)
6
13
22
1
48 (7)
48.5 (28-58)
2
11
23
2
17
6
13
0.57 38
49
15
0.33 44
52
6
0.77 82
7
5
8
54 (11)
52 (29-74)
3
68 (13)
66 (50-104)
13
12.9 (1.7)
12 (11-17)
13
24
6
4
27 (5)
26 (19-38)
9
14
16
4
48 (6)
49 (35-54)
1
6
21
7
9
4
21
0.44 56 (12)
55 (29-86)
5
0.14 65 (13)
64 (39-104)
44
0.081 12.8 (1.6)
13 (7-17)
29
0.99 73
21
8
0.97 27 (6)
26 (17-39)
23
0.90 40
55
7
0.64 48 (6)
49 (28-58)
5
0.94 22
65
15
0.64 36
17
49
P-values calculated from tests for trend.
Table IV Prognostic significance of oestrone sulphatase level and node status
Time to recurrence Overall survival
Variable Number Obs. Exp. P-value Obs. Exp. P-value
Oestrone sulphatase
Low 28 12 13.1 8 10.2
Medium 35 17 13.2 0.815 10 9.3 0.449
High 31 9 11.7 9 7.6
Node status
Negative 48 10 20.0 0.001 6 13.1 0.004
Positive 36 22 12.0 16 8.9
All P-values calculated from log-rank test for trend.
cases in the high-activity group. There was no significant
difference between these groups (P= 0.77).
The association of intratumoral oestrone sulphatase with
the other putative prognostic factors is shown in Table III.
There was no significant correlation between the enzyme level
and body weight at the time of diagnosis, parity, age at first
pregnancy, tumour size, menopausal status at diagnosis, age
at menopause and family history of breast cancer.OESTRONE SULPHATASE AS PROGNOSTIC FACTOR 559
Time to disease recurrence (Table IV)
The time to disease recurrence from primary treatment, or
the time to disease progression in patients with advanced
disease, was recorded. The percentage probability recurrence
rate for each of 10 years of follow-up was calculated. For the
low-activity group, 12 of 28 patients suffered relapse/
recurrence in the follow-up period, as did 17 of 35 patients in
the medium-activity group and 9 of 31 patients in the high-
activity group in the same time period. The log-rank test for
trend showed no significant correlation between enzyme
activity and time to disease recurrence or disease relapse
(P = 0.82). The plot of percentage probability recurrence free
against years since primary treatment is shown in Figure 2.
Overall survival time (Table IV)
The overall survival from the time that the initial biopsy was
taken (from which the oestrone sulphatase activity was deter-
mined) was recorded, that is the overall survival time from
initial diagnosis or, in some cases, the overall survival time
from local recurrence. In the low-activity group, 8 of 28
patients had died, in the medium-activity group 10 of 35
patients had died and in the high-activity group 9 of 31
patients had died. The percentage probability of survival for
the three groups was calculated and plotted against years
from primary treatment (Figure 3). The log-rank test for
trend showed no significant correlation between the overall
survival time and the enzyme activity level (P = 0.45).
Time to recurrence by node status (Table IV)
In this series of patients, 22 of 36 node-positive patients had
suffered recurrence or relapse in the follow-up period, but
only 10 of 48 node-negative patients. The percentage pro-
bability of being recurrence free was calculated and plotted
against years of follow-up (Figure 4). The log-rank test for
trend confirmed that node-negative patients had a signifi-
cantly longer time to recurrence than node-positive patients
(P = 0.001).
Overall survival time by node status (Table IV)
In the period of follow-up, 16 of 36 node-positive patients
died, and only 6 of48 node-negative patients. The percentage
probability of survival was calculated and plotted against
years of follow-up (Figure 5). The log-rank test for trend
confirmed that node-negative patients have a significantly
prolonged overall survival time compared with node-positive
patients (P = 0.004).
Relationship ofintratumoral oestrone sulphatase activity to
prognosticfactors in post-menopausal women
The above analyses were repeated for the 55 patients in this
study who were post-menopausal. There was no significant
correlation in this group ofpatients between the intratumoral
oestrone sulphatase level and OR status (P = 0.586), node
status (P = 0.976), age at diagnosis (P = 0.21), histology
(P = 0.928) or any of the other prognostic factors studied.
These results are shown in Table V.
Relationship ofintratumoral oestrone sulphatase to outcome
after adjuvant tamoxifen therapy
Only 21 patients received adjuvant tamoxifen (20 mg daily)
therapy at diagnosis. The median oestrone sulphatase activity
(0.041 nmolmin-' mg-'; range 0-0.399) was significantly
higher in patients who did not relapse (n = 12; follow-up of
12-38 months) than in patients who relapsed (n = 9, follow-
up of 1-28 months) after adjuvant tamoxifen therapy (mean
activity 0.021; range 0-0.093 nmol min' mg-'), P<0.05
(Mann-Whitney test). However this difference was no longer
significant if only OR-positive patients were analysed
(n= 16).
a) a)
a)
0
c
(D
L) .
0
.0 a- 0
100
80
60F
40h
20
0 1 2 3 4 5 6 7 8
Years since primary operation
9 10
Figure 2 The time to recurrence demonstrated as percentage
probability recurrence free vs years since primary treatment for
low (---, 12/28), medium ( , 17/35) and high ( , 9/31)
oestrone sulphatase activity.
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Figure 3 Overall survival expressed as percentage probability of
survival vs years since primary treatment for low ( , 8/28),
medium ( , 10/35) and high ( , 9/31) oestrone sulphatase
activity.
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negative, 10/48; ---, node positive, 22/36) expressed as percen-
tage probability of recurrence free vs years since primary treat-
ment.
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Table V Oestrone sulphatase activity in breast cancer
Low Medium High Overall
Variable (n = 17) (n = 22) (n = 16) P-value (n = 55)
Node status
+ve
- ve
Not known
OR status
+ve
- ve
Not known
Histology
IDC
Lobular
DCIS
Not known
Age at diagnosis
Mean (s.d.)
Median (range)
Not known
Weight (kg)
Mean (s.d.)
Median (range)
Not known
Age at menarche
Mean (s.d.)
Median (range)
Not known
Tumour size
T1/T2
T3/T4
Not known
Parity
Yes
No
Not known
Age at first pregnancy
Mean (s.d.)
Median (range)
Not known
Age at menopausal
Mean (s.d.)
Median (range)
Not known
Family history
Yes
No
Not known
7
8
2
9
6
2
16
0
1
0
8
13
12
10
0
18
2
2
0
66 (9)
63 (54-86)
0
63 (11)
67 (41-75)
8
11.8 (5.6)
12.5 (7-14)
5
6
4
7
12
4
1
29 (6)
30 (21-39)
9
49 (8)
51.5 (35-56)
5
2
13
2
6
8
2
7
8
1
13
1
0
2
66 (8)
64.5 (50-80)
0
67 (14)
67 (39-93)
9
13.5 (1.5)
14 (9-16)
1
9
3
10
16
6
0
28 (7)
26 (19-39)
10
48 (7)
48.5 (28-58)
2
5
15
2
0.976 21
28
5
0.586 28
24
3
0.928 47
3
3
2
62 (7)
60 (48-74)
0
67 (11)
67 (53-93)
12.8 (1.8)
12 (11-17)
5
5
2
9
12
3
1
28 (7)
25.5 (19-38)
6
48 (6)
49.5 (35-54)
2
4
10
2
0.21 65 (8)
63 (48-86)
0
0.415 66 (12)
67 (39-93)
18
0.139 12.8 (1.9)
13.5 (7-17)
11
0.767 20
9
26
0.916 40
13
2
0.602 28 (6)
26.5 (19-39)
25
0.518 48 (7)
49 (28-58)
9
0.447 11
38
6
All P-values calculated from tests from trend.
Discussion
The cause of breast cancer is not known. However
epidemiological evidence suggests that increased incidence is
associated with endocrine, environmental and genetic factors.
Early menarche, age at the menopause, age at first pregnancy
and the parity of the patient all show correlation with
incidence of breast cancer (McMahon et al., 1973). In addi-
tion, women with a family history of breast cancer are at
increased risk of developing breast cancer, with a relative risk
of 1.7-2.5 for women with a first-degree relative with breast
cancer (Adami et al., 1981). However, there is no significant
correlation between intratumoral oestrone sulphatase activity
and age at onset of menarche, age at onset of menopause,
parity of the patients, age at first pregnancy, family history
and menopausal status of the patient at the time of diag-
nosis. Moreover, this study confirms the earlier reports which
suggested that there was no significant correlation between
enzyme activity and the presence of the oestrogen receptor.
Although there is an association between aromatase.activity
and histological grade (Silva et al., 1989), there is no relation-
ship between oestrone sulphatase activity and histological
subtype, although information on the grade of histology was
not available in this study. However, it should be noted that
most tumours in this study were IDC. For those tumours at
the time of diagnosis, and for those advanced or recurrent
tumours at the time of biopsy, there was no association
between enzyme activity and either time to recurrence (or to
disease progression) or overall survival time. Nor was there
significant correlation of enzyme activity with any of the
prognostic factors studied when the data were analysed for
post-menopausal women alone. However, only 55 patients
were post-menopausal, and this number is too small to allow
survival curves to be calculated for this subgroup 41one.
Furthermore, as this study was performed with only 102
samples, there is insufficient power to detect modest associa-
tions as statistically significant. However, such modest
associations are unlikely to be of significance in clinical
practice.
Patients with histologically negative axillary lymph node
involvement have a significantly greater probability of sur-
vival than patients with positive histological lymph nodeOESTRONE SULPHATASE AS PROGNOSTIC FACTOR 561
involvement (Payne et al., 1970; Haagensen, 1977; Valagossa
et al., 1978). The presence and extent of axillary lymph node
involvement is the single most important prognostic factor
for breast cancer. There was no relationship between nodal
status and oestrone sulphatase activity. However, this study
confirmed that node-negative patients have a significantly
longer time to recurrence and a longer overall survival.
In our previous study, aromatase activity did not correlate
with survival (Silva et al., 1989), yet the role of aromatase
inhibitors in the management of advanced breast cancer is
well established (Coombes & Evans, 1991). Although intra-
tumoral oestrone sulphatase activity at the time of diagnosis
is of no prognostic value, the enzyme is an important source
of oestrogens for maintaining growth of hormone-dependent
tumours in post-menopausal women, and potent inhibitors of
this enzyme may well be a useful therapeutic manoeuvre. The
value of intratumoral oestrone sulphatase activity in predic-
ting outcome of adjuvant tamoxifen therapy cannot be as-
sessed in this study because of inadequate patient numbers.
The importance of the intratumoral enzyme level in predict-
ing response to endocrine therapy in advanced or metastatic
breast cancer remains to be established, and would be an
interesting further study.
This work was supported by grants from the Cancer Research
Campaign.
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